Gilead Pharmaceuticals (GILD +3%) tacks on another gain today, adding to yesterday's +4% run on...

|About: Gilead Sciences, Inc. (GILD)|By:, SA News Editor

Gilead Pharmaceuticals (GILD +3%) tacks on another gain today, adding to yesterday's +4% run on the back of yesterday's update on ION-1, a Phase 3 clinical trial evaluating a combination of sofosbuvir and ledipasvir with and without ribavirin for treating the hepatitis C virus infection. A review by the study's Data and Safety Monitoring Board concluded that the trial should continue without modification. ISI says the treatment could see sales of $6B or more during either 2014 or 2015.